A5314 is a phase II, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of low dose methotrexate (LDMTX) for the treatment for HIV-associated inflammation. The ancillary study will assess the impact of anti-inflammatory treatment with LDMTX on arterial inflammation, as assessed by FDG-PET/CT imaging in virally suppressed HIV-infected individuals already taking part in the main A5314 protocol.
|Effective start/end date||8/31/15 → 5/31/17|
- Massachusetts General Hospital (224883 / R01HL122177)
- National Heart, Lung, and Blood Institute (224883 / R01HL122177)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.